N/A
Completed N=328
The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System
Source: ClinicalTrials.gov NCT04129125 ↗Enrolled (actual)
328
Serious AEs
36.5%
Results posted
Aug 2025
Primary outcomePrimary: ITT Cohort: Rate of Core Lab-adjudicated Reperfusion Success — 216 Participants — p=<0.0001
Summary
The trial is designed to assess the safety and efficacy of using the Zoom Reperfusion System in subjects diagnosed with acute ischemic stroke and undergoing a thrombectomy procedure within 8 hours of last known well.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY ITT Cohort: Rate of Core Lab-adjudicated Reperfusion Success |
216 | <0.0001 sig |
| PRIMARY ITT Cohort: Rate of Symptomatic Intracranial Hemorrhage (sICH), as Independently Adjudicated by Core Lab and Safety Board |
5 | — |
| PRIMARY FDA Clearance Cohort: Rate of Core Lab-adjudicated Reperfusion Success |
177 | 0.0001 sig |
| PRIMARY FDA Clearance Cohort: Rate of Symptomatic Intracranial Hemorrhage (sICH), as Independently Adjudicated by Core Lab and Safety Board |
2 | — |
| PRIMARY FDA Clearance Cohort for Distal ICA/M1 Occlusions: Rate of Core Lab-adjudicated Reperfusion Success |
125 | — |
| PRIMARY FDA Clearance Cohort for Distal ICA/M1 Occlusions: Rate of Symptomatic Intracranial Hemorrhage (sICH), as Independently Adjudicated by Core Lab and Safety Board |
1 | — |
| SECONDARY ITT Cohort: Time to Achieve mTICI Score ≥ 2b |
19 | — |
| SECONDARY ITT Cohort: Rate of mTICI Score 3 Reperfusion |
78 | — |
| SECONDARY ITT Cohort: Rate of First Pass Success |
148 | — |
| SECONDARY ITT Cohort: Rate of mTICI Score 2c Reperfusion |
147 | — |
| SECONDARY ITT Cohort: Rate of Functional Independence |
133 | — |
| SECONDARY ITT Cohort: Quality of Life Assessment |
71.5; 71; 79.9; 78.9; 85; 76.3 | — |
| SECONDARY ITT Cohort: Rate of All-Cause Mortality |
33 | — |
| SECONDARY ITT Cohort: Rate of All Intracranial Hemorrhage (ICH) |
53 | — |
| SECONDARY ITT Cohort: Rate of Embolization in New Territory (ENT) |
2 | — |
| SECONDARY ITT Cohort: Rate of Serious Adverse Device Effects (SADEs) |
5 | — |
| SECONDARY ITT Cohort: Rate of Serious Adverse Events |
95 | — |
| SECONDARY FDA Clearance Cohort: Time to Achieve mTICI Score ≥ 2b |
19 | — |
| SECONDARY FDA Clearance Cohort: Rate of mTICI Score 3 Reperfusion |
65 | — |
| SECONDARY FDA Clearance Cohort: Rate of First Pass Success |
128 | — |
| SECONDARY FDA Clearance Cohort: Rate of mTICI Score 2c Reperfusion |
124 | — |
| SECONDARY FDA Clearance Cohort: Rate of Functional Independence |
110 | — |
| SECONDARY FDA Clearance Cohort: Quality of Life Assessment |
72.7; 72.4; 79.8; 79.2; 85.7; 77.8 | — |
| SECONDARY FDA Clearance Cohort: Rate of All-Cause Mortality |
26 | — |
| SECONDARY FDA Clearance Cohort: Rate of All Intracranial Hemorrhage (ICH) |
42 | — |
| SECONDARY FDA Clearance Cohort: Rate of Embolization in New Territory (ENT) |
2 | — |
| SECONDARY FDA Clearance Cohort: Rate of Serious Adverse Device Effects (SADEs) |
3 | — |
| SECONDARY FDA Clearance Cohort: Rate of Serious Adverse Events |
74 | — |
| SECONDARY FDA Clearance Cohort for Distal ICA/M1 Occlusions: Time to Achieve mTICI Score ≥ 2b |
18 | — |
| SECONDARY FDA Clearance Cohort for Distal ICA/M1 Occlusions: Rate of mTICI Score 3 Reperfusion |
46 | — |
| SECONDARY FDA Clearance Cohort for Distal ICA/M1 Occlusions: Rate of First Pass Success |
87 | — |
| SECONDARY FDA Clearance Cohort for Distal ICA/M1 Occlusions: Rate of mTICI Score 2c Reperfusion |
84 | — |
| SECONDARY FDA Clearance Cohort for Distal ICA/M1 Occlusions: Rate of Functional Independence |
67 | — |
| SECONDARY FDA Clearance Cohort for Distal ICA/M1 Occlusions: Quality of Life Assessment |
69; 69.4; 76.5; 78.6; 84.7; 74.6 | — |
| SECONDARY FDA Clearance Cohort for Distal ICA/M1 Occlusions: Rate of All-Cause Mortality |
21 | — |
| SECONDARY FDA Clearance Cohort for Distal ICA/M1 Occlusions: Rate of All Intracranial Hemorrhage (ICH) |
29 | — |
| SECONDARY FDA Clearance Cohort for Distal ICA/M1 Occlusions: Rate of Embolization in New Territory (ENT) |
2 | — |
| SECONDARY FDA Clearance Cohort for Distal ICA/M1 Occlusions: Rate of Serious Adverse Device Effects (SADEs) |
3 | — |
| SECONDARY FDA Clearance Cohort for Distal ICA/M1 Occlusions: Rate of Serious Adverse Events |
54 | — |
Eligibility Criteria
Inclusion Criteria
- Age 18 and older
- NIHSS >=6
- The operator feels that the stroke can be treated with endovascular thrombectomy approaches and the interventionalist estimates that groin puncture can be achieved within 8 hours from time last seen well
- Pre-event mRS scale 0-1
- Large vessel occlusion of the intracranial internal carotid artery (ICA), middle cerebral artery (MCA)-M1 or M2 segments, basilar, or vertebral arteries as evidenced by MRA or CTA
- For strokes in anterior circulation, ASPECTS >=6; For strokes in posterior circulation, pc-ASPECTS >=8
- Non-contrast CT/CTA or MRI/MRA for trial eligibility performed or repeated at treating stroke center or outside medical facility within 2 hours of treatment initiation
- If indicated per American Heart Association clinical guidelines, thrombolytic therapy should be administered as soon as possible
- Consenting requirements met according to local IRB or Ethics Committee
Exclusion Criteria
- Female known to be pregnant at time of admission
- Patient has suffered a stroke in the past 3 months
- Presence of an existing or pre-existing large territory infarction
- Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluation, e.g., dementia with prescribed anti-cholinesterase inhibitor
- Known history of severe contrast allergy or absolute contraindication to iodinated contrast
- Clinical history, past imaging or clinical judgement suggest that the intracranial occlusion is chronic
- Life expectancy of less than 6 months prior to stroke onset
- Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories
- Subject participating in another clinical trial involving an investigational device or drug
- Known cancer with metastases
- Evidence of active systemic infection
- Any known hemorrhagic or coagulation deficiency
Imaging Exclusion Criteria:
- Evidence of intracranial hemorrhage on CT/MRI
- CTA or MRA evidence of carotid stenosis requiring treatment for intracranial access
- Excessive vascular access tortuosity or target vessel size that will likely prevent endovascular access with the Imperative Care 0.088" ID Catheters
- Intracranial stent implanted in the same vascular territory that would preclude the safe deployment/removal of the thrombectomy devices
- Occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior circulation/vertebrobasilar system) as confirmed on CTA/MRA, or clinical evidence of bilateral strokes or strokes in multiple territories as determined by the treating physician
- Significant mass effect with midline shift as confirmed on CT/MRI
- Evidence of intracranial tumor (except small meningioma defined as ≤ 3cm and asymptomatic) as confirmed on CT/MRI
- Angiographic evidence of pre-existing arterial injury, e.g., carotid dissection, complete cervical carotid occlusion, or vasculitis
Data sourced from ClinicalTrials.gov (NCT04129125). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.